Some women know that they in the increased risk of a developing cancer of rupture, but scientists hope that certain drugs can bridle that risk. To check up two drugs on their efficiency, scientists have begun Issledovanie Tamoksifena and Raloxifene (STAR) which as expect, will result in in 2006.

NCI which is the main thing funder research or clinical test, has made a question-and-answer the fact sheet online for the people interested in a cognizance more about the STAR. The name of the market for тамоксифена - Nolvadex®, and the name for raloxifene - Evista®.

Examining in more than 400 centres through the United States, Puerto Rico, and Canada, are the National Surgical Auxiliary Project of the Breast and the Gut. The registration closed in June 2004, after test, has achieved the object 19 000 concerning the period after менопаузы women.

Tags: Evista, Raloxifene

This entry was posted on Пятница, Октябрь 2nd, 2009 at 15:07 and is filed under Woman Health. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.